Onward Medical N.V. (63E.F)

4.6700 +0.0600 (+1.30%) As of 09:59AM CEST. Market open.

Onward Medical N.V.

Schimmelt 2
Eindhoven NL-5656
Netherlands

https://www.onwd.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 99

Key executives

Name	Title	Pay	Exercised	Year born
Mr. David L. Marver	CEO & Executive Director	767k	N/A	1968
Dr. Gregoire Courtine Ph.D.	Chief Scientific Officer & Director	N/A	N/A	1975
Mr. Khaled Bahi	Interim Chief Financial Officer	N/A	N/A	1966
Mr. Robert W. Odell	Vice President of Operations	N/A	N/A	1960
Mr. John Murphy	Chief Technology Officer	N/A	N/A	N/A
Ms. Sarah Moore	Vice President of Global Marketing	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Onward Medical N.V., a medical technology company, develops implantable neuro-stimulation Systems and non-invasive systems for electrical stimulation of specific areas of the spinal cord. The company engages in developing ARCEX, a transcutaneous system designed to improve upper extremity strength, function, and other symptoms in people with spinal cord injury (SCI); ARCIM, a minimally invasive implantable system to address blood pressure instability and other symptoms in people with SCI; and ARCBCI, which adds an implantable bran-computer interface to the ARCIM to restore thought-driven movement of the upper and lower limbs. Onward Medical N.V. was founded in 2014 and is headquartered in Eindhoven, Netherlands.

Corporate governance

Onward Medical N.V.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.